https://www.mayo.edu/research/clinical-trials/cls-20115823?&p=1
Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or...
ruxolitinib phosphatejak inhibitor
https://www.jnj.com/media-center/press-releases/janssen-enters-into-worldwide-collaboration-with-theravance-biopharma-for-oral-pan-jak-inhibitor-drug-candidate-for-the-treatment-of-inflammatory-bowel-disease
JANSSEN ENTERS INTO WORLDWIDE COLLABORATION WITH THERAVANCE BIOPHARMA FOR ORAL, PAN-JAK INHIBITOR...
https://www.biospace.com/press-releases/libertas-bio-a-formation-bio-subsidiary-license-of-gusacitinib-a-dual-jak-syk-inhibitor-to-sanofi
Libertas Bio, a Formation Bio subsidiary, License of Gusacitinib, a Dual JAK/SYK Inhibitor, to...
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1523256/full
Frontiers | Case report: JAK inhibitor treatment of immune dysregulation symptoms in a patient with...
A heterozygous mutation in the PTPN2 gene has recently been described in several patients exhibiting symptoms of immune dysregulation. The gene encodes a ubi...
https://www.mdanderson.org/newsroom/archived-news/jak-inhibitor-provides-rapid-durable-relief-for-myelofibrosis-pa.h00-158596101.html
ARCHIVED: JAK Inhibitor Provides Rapid, Durable Relief for Myelofibrosis Patients | UT MD Anderson
https://www.hmpgloballearningnetwork.com/site/allergy/news/upadacitinib-30-mg-emerges-most-effective-oral-jak-inhibitor-moderate-severe
Upadacitinib 30 mg Emerges as Most Effective Oral JAK Inhibitor for Moderate-to-Severe Atopic...
https://www.prnewswire.com/news-releases/janssen-enters-into-worldwide-collaboration-with-theravance-biopharma-for-oral-pan-jak-inhibitor-drug-candidate-for-the-treatment-of-inflammatory-bowel-disease-300594714.html
Janssen Enters Into Worldwide Collaboration With Theravance Biopharma For Oral, Pan-JAK Inhibitor...